#amiodarone #drug-induced-lung-disease #pulmonary-toxicity #antiarrhythmic-drugs #drug-toxicity

Amiodarone Pulmonary Toxicity

Definition

Amiodarone pulmonary toxicity (APT) is a spectrum of drug-induced lung injury affecting 1–15% of amiodarone-treated patients (cumulative incidence 4.2%/7.8%/10.6% at 1/3/5 years), arising from extreme pulmonary sequestration of amiodarone and its metabolite desethylamiodarone (100–500× lung-to-serum concentration ratio). A key clinical distinction separates "amiodarone effect" (ubiquitous asymptomatic lipoid pneumonia — present in virtually all treated patients, NOT a reason to stop the drug) from "amiodarone toxicity" (distinct inflammatory patterns requiring intervention). Diagnosis is by exclusion; DLCO is the earliest functional marker. Hospitalisation mortality is 21–33%; ARDS mortality ~50%.

Key Concepts

Amiodarone Effect vs Amiodarone Toxicity — Key Distinction

"Amiodarone effect" (lipoid pneumonia): Present in virtually ALL patients on chronic amiodarone; foamy macrophages occupy intra-alveolar and interstitial space; causes progressive but asymptomatic DLCO reduction in patients with normal lung reserve; NOT a reason to stop amiodarone; NOT equivalent to toxicity
"Amiodarone toxicity": Clinically distinct inflammatory lung reaction patterns requiring intervention; encompasses 9 discrete patterns (CEP, COP, AFOP, amiodaronoma, NSIP-like, IPF-like, DIP, ALI/ARDS, DAH)
Foamy macrophages in BAL = marker of exposure only, NOT toxicity; their absence makes APT unlikely but does not exclude it
sources/amiodarone-pulmonary-drugsafety-2010, rating: medium

Pathophysiologic Basis — Three Mechanisms

1. Direct cytotoxic: Amiodarone disrupts lysosomal membranes via protein C activation → releases toxic oxygen radicals → caspase pathway → apoptosis of alveolar epithelial cells (AECs); lysosomal phospholipase inhibition → phospholipid accumulation → lamellar inclusions in macrophage lysosomes
2. Immune-mediated: Th1/Th2 lymphocyte imbalance; alveolar macrophages release TNF-α and TGF-β; genetically predisposed patients are at higher risk
3. Angiotensin enzyme system: Amiodarone upregulates angiotensinogen mRNA/protein in AECs; angiotensin II (elevated in chronic HF) enhances amiodarone-induced AEC apoptosis → synergistic lung damage; mechanistically explains why ACE inhibitors/ARBs appear protective
Lung tissue concentration: 100× (Am) and 500× (DEAm) above serum — direct cytotoxicity even at therapeutic serum levels; drug persists up to 1 year after cessation; DEAm penetrates tissues ~5× more than parent molecule and acts as sustained-release reservoir
No dose or duration threshold has been established to avoid toxicity
sources/amiodarone-pulmonary-clin-chest-2004, rating: medium; sources/amiodarone-pulmonary-drugsafety-2010, rating: medium

Epidemiology and Risk Factors

Cumulative prevalence 1–15%; dose-linked but NOT strictly dose-dependent: 0.1–0.5% at ≤200 mg/day; 5–15% at ≥500 mg/day; up to 50% at 1200 mg/day
Quantitative cumulative incidence: 4.2% at 1 year → 7.8% at 3 years → 10.6% at 5 years
Age is the strongest risk factor: 3-fold increase per 10-year age increment over 60; DLCO decline accelerated in elderly
Cumulative dose: >10 g is an independent risk factor; risk persists up to 150 g cumulative; high DEAm plasma levels during maintenance = independent risk factor
Risk factors: male sex, age >40 years, cumulative exposure, pre-existing poor pulmonary function, emphysema, prior pneumonectomy
Pre-existing lung disease (AFFIRM trial data): Associated with higher rate of diagnosed APT but does NOT increase pulmonary death or all-cause mortality; cautious amiodarone use acceptable even in elderly AF patients with pre-existing lung disease; pretreatment DLCO >45% is NOT an independent risk factor for APT
ACE inhibitors / ARBs potentially protective: Two retrospective studies show lower APT rates in patients on ACE-I/ARBs (supported by angiotensin pathway mechanism); not yet standard of care
Specific high-risk scenarios: high FiO₂ during cardiac or pulmonary surgery → ARDS (~50% fatality); iodinated contrast media → fatal ARDS (cases reported); ICD implantation → ARDS up to 10%; dose doubling; sudden corticosteroid withdrawal; pulmonary angiography
Diagnosis typically made ~2 months after symptom onset — significant diagnostic delay
sources/amiodarone-pulmonary-clin-chest-2004, rating: medium; sources/amiodarone-pulmonary-drugsafety-2010, rating: medium

Clinical Patterns — Full Taxonomy

Acute Presentations

ALI/ARDS: Abrupt onset, rapid progression; ~50% fatality; diffuse bilateral infiltrates; overlapping COP + DAD histology (AFOP type); triggered by high FiO₂, cardiothoracic surgery, iodinated contrast, sudden corticosteroid withdrawal; can occur as early as day 2 of treatment or with cumulative IV doses as low as 1000–1500 mg
Diffuse alveolar haemorrhage (DAH): Rare; haemoptysis; may relate to lymphocytic vasculitis of small capillaries; antiglomerular membrane antibodies reported
Bronchospasm / angioedema: Anaphylactic-type reactions; fully reversible with treatment
sources/amiodarone-pulmonary-drugsafety-2010, rating: medium

Subacute / Chronic Presentations

Subacute infiltrative pneumonitis (most common): Progressive dyspnoea + nonproductive cough + pleuritic chest pain over weeks to months; asymmetric bilateral infiltrates; HRCT shows ground-glass opacities, high attenuation areas, subpleural distribution with right upper lobe predilection; exudative pleural effusion in up to 1/3
Chronic organising pneumonia (COP): Indistinguishable from idiopathic; bilateral consolidation + ground-glass opacities, often peripheral; migratory infiltrates; SOB, cough, fever, pleuritic pain
Chronic eosinophilic pneumonia (CEP): Rare; peripheral blood or BAL eosinophilia >25%; may be asymptomatic or with transient infiltrates
Acute fibrinous and organising pneumonia (AFOP): Variant that does not meet DAD/COP/CEP criteria; fulminant presentation with poor prognosis; intra-alveolar fibrin + organising pneumonia + type II cell hyperplasia
Nodules / masses ("amiodaronoma"): Single or multiple subpleural masses; right upper lobe predominant; PET-positive — frequent initial misdiagnosis as malignancy; may cavitate or show a halo
NSIP-like: Interstitial reticular opacities, traction bronchiectasis; more reversible than UIP pattern
IPF-like: Severe interstitial fibrosis, honeycombing at lung bases; difficult to distinguish from true IPF; amiodarone-related fibrosis appears milder and more slowly progressive; adversely impacts life expectancy
DIP (desquamative interstitial pneumonia): Acute onset; diffuse AIP with respiratory failure may require mechanical ventilation
Subclinical APT: Normal CXR but HRCT abnormalities (ground-glass, small alveolar opacities, septal lines); increased BAL inflammatory cells; reversible upon drug cessation; uncertain progression risk to overt APT
sources/amiodarone-pulmonary-clin-chest-2004, rating: medium; sources/amiodarone-pulmonary-drugsafety-2010, rating: medium

Pleural / Pericardial Involvement

Pleural effusion: rare; unilateral or bilateral; small-to-moderate exudate; lymphocytic or neutrophilic predominance; isolated effusion without parenchymal disease extremely rare
Pleural thickening: common adjacent to peripheral parenchymal lesions
Drug-induced lupus: rare; pleuropericarditis + ANA + antihistone antibodies; resolves after drug withdrawal
sources/amiodarone-pulmonary-drugsafety-2010, rating: medium

Diagnostic Approach

Clinical Algorithm

Drug history; detailed imaging (CXR + HRCT)
PFTs with DLCO vs pre-treatment baseline
BAL
Diuresis trial — partial clearing = LV failure component; persistent opacities → continue evaluating for APT
Confident diagnosis → discontinue amiodarone (under cardiological guidance); observe 1–2 months
Add corticosteroids if substantial imaging involvement or hypoxaemia
No improvement at 1–2 months → consider alternative diagnoses; consider transbronchial biopsy

sources/amiodarone-pulmonary-clin-chest-2004, rating: medium

KL-6 (MUC1 Mucin)

Expressed on type II pneumocytes; marker of alveolar epithelial cell injury
Sensitivity 25%, specificity 91%, PPV 22%, NPV 92% at cut-off >500 U/mL
High NPV = useful to rule OUT APT; insufficient alone to stop amiodarone
Also elevated in other ILDs and sarcoidosis; data from single low-dose cohort — may not generalise to high-dose regimens
sources/amiodarone-pulmonary-drugsafety-2010, rating: medium

CT Density

70 HU is suggestive of amiodarone-related lesions (iodine content)
Absent in 27–55% of patients with confirmed APT — cannot be used to rule out APT
High liver/spleen attenuation = drug deposition (not necessarily toxicity)
Differential for high-density lesions: metastatic pulmonary calcification, talcosis, iodinated oil embolism, silicoproteinosis, amyloidosis — interpret in clinical context
sources/amiodarone-pulmonary-drugsafety-2010, rating: medium

BAL

BAL indicates exposure but has no specificity for toxicity
Cellular pattern (variable): lymphocytic 21%, neutrophilic 26%, mixed 33%, normal 20%; eosinophilia in ~50% regardless of cellular profile
CD4/CD8 ratio usually <1; increases after drug discontinuation
No cellular BAL pattern predicts detrimental outcome or irreversible fibrosis
sources/amiodarone-pulmonary-drugsafety-2010, rating: medium

Lung Biopsy

Surgical lung biopsy: generally AVOID — high risk of post-procedure ARDS with rapid progression and high mortality; diagnosis is by clinical exclusion
Transbronchial biopsy: when diagnosis urgently required (pre-surgery, amiodarone cannot be stopped, no response by 1–2 months)
sources/amiodarone-pulmonary-drugsafety-2010, rating: medium

DLCO as the Key Monitoring Biomarker

Earliest functional abnormality in APT; least affected by co-existing left heart failure (unlike other PFT parameters)
Sensitivity threshold: ≥15% decrease from baseline; specificity threshold: ≥30% decrease from baseline
Isolated DLCO decrease without clinical/imaging evidence does NOT warrant stopping amiodarone (overt APT develops in only 1/3 of such patients)
Stable DLCO in serial measurements excludes clinically significant APT
Persistent post-treatment DLCO reduction common despite imaging clearance (APT + emphysema combined)
Decline significantly greater in patients with pre-existing COPD
sources/amiodarone-pulmonary-clin-chest-2004, rating: medium; sources/amiodarone-pulmonary-drugsafety-2010, rating: medium

Management

Discontinue amiodarone under cardiological supervision; substitute with another AAD or ICD in collaboration with cardiologist; drug cessation alone sufficient only for limited disease
Corticosteroids (no RCT evidence; strong observational support):
- Prednisolone 0.5–1 mg/kg/day; maintain until definite clinical + radiographic response
- Duration often 1 year (drug persists in lung tissue for up to 1 year after stopping)
- Taper slowly: ≤5 mg/day reduction — aggressive reductions trigger severe relapse; relapse risk persists up to 8 months after complete cessation
- Early withdrawal (2–3 months) → recurrence, which may be more severe and potentially fatal
If amiodarone absolutely essential: lowest possible dose + corticosteroids combination has been used successfully
Screen for multi-system toxicity at time of APT diagnosis (thyroid, liver, eye)
Regular follow-up: PFTs (disease progression), thyroid hormones (dysfunction after cessation), ECG (rhythm monitoring)
Radiographic clearing >85% at 1–3 months; residual opacities or progression to fibrosis in remainder
Patient education about APT risk is essential — early diagnosis clearly improves outcome
Mortality with hospitalisation: 21–33%; ARDS: ~50%; all rates higher in elderly
sources/amiodarone-pulmonary-clin-chest-2004, rating: medium; sources/amiodarone-pulmonary-drugsafety-2010, rating: medium

Prevention and Monitoring

Lowest effective amiodarone dose; careful patient selection
Baseline CXR + PFTs (including DLCO) mandatory before starting
High-risk patients: PFTs + imaging every 3–6 months
Standard low-dose patients: routine serial PFTs probably unrewarding; patient education + watchful waiting
Avoid high-FiO₂ ventilation in amiodarone-treated patients undergoing surgery
Caution with iodinated contrast media in amiodarone-treated patients
sources/amiodarone-pulmonary-clin-chest-2004, rating: medium

Contradictions / Open Questions

No RCT for corticosteroid efficacy in APT: All evidence is observational or case-series. Dose (0.5–1 mg/kg/day) and duration (often 1 year) recommendations are consensus-based. No head-to-head comparison of early vs delayed initiation. (sources/amiodarone-pulmonary-clin-chest-2004, sources/amiodarone-pulmonary-drugsafety-2010)
Corticosteroid taper rate: The 2010 review cautions against reductions >5 mg/day; the 2004 review recommends minimum 6 months without specifying a per-step limit. No RCT or systematic data define the optimal taper rate; aggressive tapers documented to trigger fatal relapse up to 8 months after cessation. (sources/amiodarone-pulmonary-drugsafety-2010)
Amiodarone continuation in APT: Dose reduction + corticosteroids may achieve adequate control in patients with life-threatening arrhythmias who cannot stop the drug. No systematic data exist to guide this decision. (sources/amiodarone-pulmonary-clin-chest-2004, sources/amiodarone-pulmonary-drugsafety-2010)
Isolated DLCO decrease — watch or stop?: DLCO decrease ≥15–30% without clinical or imaging evidence does NOT warrant discontinuation, since overt APT develops in only 1/3 of such patients. Counter-intuitive given the toxicity profile; requires well-calibrated threshold approach. (sources/amiodarone-pulmonary-clin-chest-2004)
ACE inhibitor/ARB protection: Two retrospective studies suggest lower APT rates in patients on ACE-I/ARBs (mechanistically supported by angiotensin pathway). Not practice-changing; not yet studied prospectively. (sources/amiodarone-pulmonary-drugsafety-2010)
KL-6 as biomarker: High NPV (92%) is useful to rule out APT, but 25% sensitivity means a negative result cannot fully exclude it. Data from a single low-dose cohort; may not generalise to high-dose regimens. (sources/amiodarone-pulmonary-drugsafety-2010)
CT density threshold unreliable: >70 HU is suggestive but absent in 27–55% of confirmed cases — cannot be used as a screening or rule-out criterion. (sources/amiodarone-pulmonary-drugsafety-2010)
Prior amiodarone exposure as a risk factor for idiopathic pulmonary fibrosis: Suggested but not established. The irreversible nature of Am-induced fibrosis and its histological overlap with NSIP/UIP raises this question without resolution. (sources/amiodarone-pulmonary-clin-chest-2004)

Connections

Related to entities/Amiodarone — causative drug; full pharmacokinetics, indications, and multisystem toxicity
Related to concepts/Amiodarone-Induced-Thyroid-Disorders — co-occurring toxicity; thyrotoxicosis can amplify dyspnoea and exacerbate APT symptoms
Related to concepts/Drug-Induced-Arrhythmia — amiodarone arrhythmia management context; pulmonary toxicity may force discontinuation
Related to entities/Heart-Failure — key differential for APT (interstitial pulmonary oedema); diuresis trial pivotal; HF elevates angiotensin II → enhances APT risk